BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity

•BNT162b2 vaccine reactogenicity is attributable to pre-existing T-cell immunity.•Systemic reactogenicity is associated with the severity of previous COVID-19.•Systemic reactogenicity expresses an immunity-boosting effect. We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2021-12, Vol.39 (51), p.7367-7374
Hauptverfasser:	Vizcarra, Pilar, Haemmerle, Johannes, Velasco, Hector, Velasco, Tamara, Fernández-Escribano, Marina, Vallejo, Alejandro, Casado, José L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Asymptomatic BNT162 Vaccine BNT162b2 mRNA vaccine Booster effect Cell-mediated immunity Clinical trials Coronaviruses COVID-19 COVID-19 Vaccines Cross-reactivity Cytokines Dosage Drug dosages Flow cytometry Glycoproteins Humans Immunity Infections Lymphocytes T Medical personnel mRNA Oxygen saturation Peptides Reactogenicity RNA, Messenger - genetics SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Short Communication T-cell responses Vaccines Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!